Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the company’s VMS+ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. The submission, which qualifies for the NMPA’s “green channel” expedited review pathway, marks a critical step in Ventripoint’s global expansion and underscores the growing demand for advanced cardiac imaging solutions in one of the world’s largest healthcare markets.
Cardiovascular disease is the leading cause of death in China, affecting an estimated 330 million patients. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness, portability, and scalability across both urban and rural settings. However, variability in image interpretation and limited access to advanced modalities like MRI have created a pressing need for AI-driven tools that enhance diagnostic accuracy and workflow efficiency.
Ventripoint’s VMS+ 4.0 addresses this gap by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by the company’s proprietary Knowledge Based Reconstruction technology, the platform enables clinicians to assess all four chambers of the heart with high accuracy, supporting the diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption. China’s scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
The green channel designation is reserved for innovative medical technologies that address significant clinical needs, and it is expected to streamline the regulatory timeline and facilitate faster market access. For Ventripoint, this milestone validates both its technology and international strategy.
“Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy,” said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly.”
The implications for the Chinese healthcare system are significant. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to expand access to high-quality cardiac care across China’s vast and diverse population. The technology could help reduce diagnostic variability, improve patient outcomes, and alleviate the burden on specialized imaging centers.
Ventripoint’s VMS+ products are already supported by regulatory approvals in the U.S., Europe, and Canada, and are compatible with all major ultrasound vendors. The submission in China represents the next frontier in the company’s mission to democratize advanced cardiac imaging. The company has pledged to provide further updates as the regulatory review progresses.
